针对IGF1,通过调节能量消耗和脂肪沉积来缓解肥胖症
Ping Rong1,2, Yinqiu Mu1,2, Meiqin Wang1,2
1State Key Laboratory of Pharmaceutical Biotechnology, Department of Endocrinology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Model Animal Research Center, Nanjing University, Nanjing, 210061, China.
胰岛素类生长因子1 (IGF1) 的升高通过增加脂肪生产和减少能源消耗来驱动肥胖. 降低IGF1的调节或使用像柏柏林这样的AMPK激活剂可以对抗肥胖.
科学领域:
- 代谢研究研究 代谢研究
- 内分泌学 在内分泌学.
- 肥胖病原体的产生
背景情况:
- 胰岛素类生长因子1 (IGF1) 调节细胞缩和脂质生成,是肥胖发展的关键.
- 在肥胖病原体中IGF1的体内作用尚未完全理解.
- 在肥胖个体和动物模型的脂肪组织中,IGF1水平升高.
研究的目的:
- 调查IGF1在肥胖发展中的体内作用.
- 探索针对IGF1治疗肥胖症的治疗潜力.
主要方法:
- 在肥胖的人类和动物脂肪组织中分析IGF1表达.
- 在高分泌小鼠模型中,IGF1的基因下调.
- 对饮食诱导的肥胖模型的评估.
- 对柏柏林对IGF1分泌和肥胖的影响的评估.
主要成果:
- 在肥胖中增加IGF1表达与增加脂质基因表达和减少能量消耗相关.
- 在基因小鼠模型中,基因IGF1减少使脂质生成正常化,纠正能量代谢,改善肥胖.
- 降低IGF1的调节也减轻了饮食引起的肥胖.
- 柏柏林是一种AMPK激活剂,抑制了IGF1分泌,降低了脂原基因表达,降低了脂肪度.
结论:
- IGF1的过分分泌是肥胖发展的关键驱动因素.
- 针对IGF1,可能通过柏柏林等AMPK激活剂,为减轻肥胖提供了一个有前途的治疗策略.
更多相关视频
06:28A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin: The Receptor and Signaling Pathways
Regulation of Food Intake
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
TGF - β Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
